bioRxivCancer BiologyPreprint
Chromosomal instability can favor macrophage-mediated immune response and induce a broad, vaccination-like anti-tumor IgG response
B. H. Hayes, M. Wang, H. Zhu, S. H. Phan, J. C. Andrechak, A. H. Chang, L. J. Dooling, M. P. Tobin, T. Marchena, D. Discher
Abstract
Chromosomal instability (CIN), a state in which cells undergo mitotic aberrations that generate chromosome copy number variations, generates aneuploidy and is thought to drive cancer evolution. Although associated with poor prognosis and reduced immune response, CIN generates aneuploidy-induced stresses that could be exploited for immunotherapies. In such contexts, macrophages and the CD47-SIRP checkpoint are understudied. Here, CIN is induced pharmacologically induced in poorly immunogenic B16F10 mouse melanoma cells, generating persistent micronuclei and diverse aneuploidy while skewing macrophages towards an anti-cancer M1-like phenotype, based on RNA-sequencing profiling, surface marker expression and short-term antitumor studies. These results further translate to in vivo efficacy: Mice bearing CIN-afflicted tumors with wild-type CD47 levels survive only slightly longer relative to chromosomally stable controls, but long-term survival is maximized when combining macrophage-stimulating anti-tumor IgG opsonization and some form of disruption of the CD47-SIRP checkpoint. Survivors make multi-epitope, de novo anti-cancer IgG that promote macrophage-mediated phagocytosis of CD47 knockout B16F10 cells and suppress tumoroids in vitro and growth of tumors in vivo. CIN does not greatly affect the level of the IgG response compared to previous studies but does significantly increase survival. These results highlight an unexpected therapeutic benefit from CIN when paired with maximal macrophage anti-cancer activity: an anti-cancer vaccination-like antibody response that can lead to more durable cures and further potentiate cell-mediated acquired immunity.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Titrating CD47 by mismatch CRISPRi reveals incomplete repression can eliminate IgG-opsonized tumors but CD47 heterogeneity limits induction of anti-tumor IgG
B. H. Hayes, H. Zhu, … D. E. Discher·bioRxiv·Sep 27, 2022
- An immune-stimulating antibody conjugate spatiotemporally targeting CD47 and TLR9 elicits macrophage-dependent tumor clearance and durable anti-cancer adaptive immunity
Byoungjae Kong, Seung Woo Chung, … Jung Soo Suk·bioRxiv·Jul 23, 2026
- CD47 predominates over CD24 as a macrophage immune checkpoint in cancer.
Juliet Allen, Anna Meglan, … Kipp Weiskopf·bioRxiv·Nov 25, 2024
- Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer
S. Kandala, L. Voith von Voithenberg, … R. Sotillo·bioRxiv·Jun 16, 2022
- Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
L. Ding, L. Sun, … W. HUGO·Frontiers in ImmunologyPeer-reviewed·Jun 26, 2023
- MYC Overexpression Drives Immune Evasion in Human Cancer that is Reversible Through Restoration of Pro-Inflammatory Macrophages
R. Dhanasekaran, A. S. Hansen, … D. W. Felsher·bioRxiv·May 13, 2022